Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid in vitro and in vivo

Drug Delivery
Weijie LiGuangya Xiang

Abstract

Overexpression of Bmi1 gene is an important feature of cancer stem cell in various human tumors. Therefore, Bmi1 gene can be a potential target for small interfering RNA (siRNA) mediated cancer therapy. Ursolic acid (UA) as a natural product plays a pivotal role in anti-tumor field, although its performance is limited by low bioavailability and poor hydrophilicity. A folate receptor-targeted cationic liposome system was designed for the purpose of investigating the relationship between Bmil siRNA and UA. The folate receptor-targeted cationic liposomes co-delivering UA and Bmi1 siRNA (FA-UA/siRNA-L) were fabricated by electrostatic interaction between folate UA liposome (FA-UA-L) and Bmi1 siRNA. Tumor growth is inhibited by FA-UA/siRNA-L in vitro and in vivo and this inhibition is contributed by a synergistic anti-tumor effect of UA and Bmi1 siRNA. The western blot measurement of apoptosis-protein and cancer stem cell (CSC) marked-protein demonstrated that UA led to activation-induced tumor cell death and Bmi1 siRNA resulted in inhibition of cancer stem cells. Overall, these results indicate that Bmi1 as a regulating gene for cancer stem cell is an effective target for cancer treatment using siRNA and co-delivery of UA and Bmi1 ...Continue Reading

References

Jun 14, 2003·Molecular Therapy : the Journal of the American Society of Gene Therapy·John C Morris
Dec 8, 2005·Cancer Chemotherapy and Pharmacology·Jubo LiuChristine Allen
Aug 4, 2007·Gastroenterology·Tetsuhiro ChibaHideki Taniguchi
Oct 16, 2007·Cancer Cell·Sophia W M BruggemanMaarten van Lohuizen
Feb 9, 2008·International Journal of Pharmaceutics·Guangya XiangRobert J Lee
Jul 2, 2008·Laboratory Investigation; a Journal of Technical Methods and Pathology·Motoko SasakiYasuni Nakanuma
Jul 26, 2008·Nature Nanotechnology·Wendy R SanhaiMauro Ferrari
Jan 31, 2009·Nature Reviews. Drug Discovery·Jia JiaYu Zong Chen
May 9, 2009·Advanced Drug Delivery Reviews·Yu-Kyoung Oh, Tae Gwan Park
Nov 26, 2009·Molecular Cancer Research : MCR·Chuan-Rui XuXin Chen
Feb 18, 2011·The New England Journal of Medicine·Janet WoodcockRachel E Behrman
Apr 23, 2013·The FEBS Journal·Hong-Bo WangMu-Sheng Zeng
Jun 4, 2013·Nature Cell Biology·Brian BiehsOphir D Klein
Jul 4, 2013·Molecular and Cellular Biochemistry·Wu LiangWenlian Xie
Dec 19, 2015·Genes & Development·Roberta FerrettiJacqueline A Lees
Mar 17, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Haruka NishidaTomoyuki Fujii
Sep 8, 2016·International Journal of Molecular Medicine·Zefeng ZhangWeihong Sha
Nov 9, 2016·Nature Communications·Felicia GrayTomasz Cierpicki
Jun 24, 2017·Expert Opinion on Therapeutic Patents·Hidayat HussainIshtiaq Ahmed
Sep 15, 2018·International Journal of Nanomedicine·Peizhi ZhouYuquan Wei
Oct 24, 2018·Oncogene·David BakhshinyanSheila K Singh

❮ Previous
Next ❯

Citations

Jan 16, 2021·F1000Research·Saffiya HabibMoganavelli Singh
Feb 4, 2021·Acta Pharmaceutica Sinica. B·Hongxia DuanWei Huang
Aug 13, 2021·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Jian SunZhaowei Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
PCR
AFM
fluorescence microscopy

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis